U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma – NASDAQ (US) Website
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey – BeiGene LTD
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication – NASDAQ (US) Website
BeiGene Presents Positive Data in Various Lymphomas at EHA2021 | BioSpace
Novartis returns PD-1 to BeiGene in another cancer drug divorce
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® | BGNE Stock News
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA | NewBridge Pharmaceuticals
BeiGene opens European headquarters in Basel | S-GE
Press Releases – NASDAQ (US) Website
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Business Wire
BEIGENE LTD. ADS quote - Financial instrument overview - NASDAQ Stocks
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China – NASDAQ (US) Website
BeiGene Announces Pricing of $750 Million Public Offering
BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01
Paul Smart posted on LinkedIn
BeiGene, Ltd. 百濟神州有限公司
BeiGene accueille au sein de son conseil d'administration, Olivier Brandicourt, dirigeant expérimenté dans le domaine des sciences du vivant | Business Wire
BeiGene recoups cancer drug Tevimbra from Novartis
Articles about BeiGene
Articles about BeiGene
BeiGene: Building a Chinese Oncology Powerhouse (NASDAQ:BGNE) | Seeking Alpha
